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The Evolution of Myocardial Infarction: When the Truths We
Hold To Be Self-Evident No Longer Have Evidence
David D. Waters, MD,a and Sripal Bangalore, MD, MHAb
aDivision of Cardiology, University of California, San Francisco at Zuckerberg San Francisco General Hospital, San Francisco, CA
bDivision of Cardiology, New York University School of Medicine, New York, NY
See article by Bastiany et al., pages 1229e1236 of this issue.How Myocardial Infarction Used to Be
Myocardial infarction (MI) used to be a deadly and nearly
untreatable disease. Half a century ago before the advent of
reperfusion therapy, half of patients with MI had heart failure
as a complication,1 ventricular ﬁbrillation was so common
that prophylactic intravenous lidocaine was widely advo-
cated,2 and nearly one-quarter experienced pericardial friction
rub.3 When was the last time you heard a friction rub caused
by MI? In-hospital mortality exceeded 25%.4,5
Most MIs then left a large transmural zone of dead
myocardium distal to a total occlusion in a major coronary
artery. Functionally, this zone was akinetic or dyskinetic and
electrophysiologically, it was the source of life-threatening
ventricular arrhythmias. Left ventricular (LV) thrombi
frequently formed on these akinetic segments, particularly if
the location was anterior, and ventricular or septal rupture was
a feared early complication.
Since then, treatment has advanced by large and small
increments, based on the results of well-designed clinical trials.
Improvements in care include the adoption of drugs that
improve outcomesdsuch as b-blockers, angiotensin-
converting enzyme (ACE) inhibitors, statin drugs, and anti-
platelet agentsdand the rejection of drugs that are harmful,
speciﬁcally some antiarrhythmic drugs. Reperfusion therapy
was a particularly giant step forward. An open infarcterelated
artery limits myocardial damage and associated complications
and improves long-term outcome.Prophylactic Anticoagulation to Prevent Mural
Thrombus and Embolization
But do the results of all the important clinical trials and
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nadian Journal of Cardiology, the study by Bastiany et al.6
addresses this question for a speciﬁc subpopulation: patients
with anterior ST-elevation MI (STEMI) with apical systolic
dysfunction6: Should they receive prophylactic anti-
coagulation to prevent the development of LV thrombus and
systemic embolization? Both the American College of
Cardiology/American Heart Association and the European
Society of Cardiology guidelines give a weak class IIb (level of
evidence C) recommendation for anticoagulation in such
patients.7,8
As summarized by Bastiany et al.,6 the studies that
address this issue are few and inconclusive. In the pre-
thrombolytic era when LV thrombus was a common
consequence of large anterior STEMI, 2 of 6 small studies
(including small randomized trials) showed a beneﬁt of
anticoagulation. In the modern era, among patients under-
going primary percutaneous intervention and receiving dual-
antiplatelet therapy (DAPT), anticoagulation with a vitamin
K antagonist appears to be more harmful than beneﬁcial,
although the evidence is weak. Anticoagulation does appear
to reduce the risk of systemic embolization among patients
with a documented thrombus, but such patients are far less
common than they used to be. The combination of a
changing underlying substrate of MI because of reperfusion
and changing medical therapy, particularly DAPT, likely
explain the differences between studies in the pre-reperfusion
and modern eras.
The realization that the characteristics of most MIs have
changed along with concomitant therapy from the era when
many post-MI trials were executed, should lead us to recon-
sider whether or not the results of these trials still apply. More
recent clinical trials have shown that in patients taking oral
anticoagulants plus DAPT, the risk of bleeding at 1 year is as
high as 44%.9 The lower prevalence of LV thrombus com-
bined with this increased bleeding risk has shifted the balance
against triple therapy so that it now causes more harm
(bleeding) than beneﬁt (prevention of emboli).
The beneﬁt-to-risk ratio of therapies depends on the
underlying risk of the cohort. Therapies that provedll rights reserved.
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Volume 33 2017beneﬁcial decades ago may prove to be less effective or even
harmful in contemporary practice as other treatment im-
proves and risk decreases. Such shifts force us to continue to
evaluate the value of our therapies, as illustrated in the
following section.Favours β-Blockers Favours Control
Figure 1. Differential effect of b-blockers on mortality in patients who
have experienced myocardial infarction in the pre-reperfusion and
reperfusion eras. BB, b-blockers; IRR, incident rate ratio. Data from
Bangalore et al.10b-Blockers After Myocardial Infarction
Should we continue to treat all patients after MI with
b-blockers? Clinical trials done before the advent of reperfu-
sion therapy clearly demonstrate that b-blockers reduced
mortality, reinfarction, and angina in MI survivors.10 It was
recognized even in that era that the beneﬁts of b-blockers were
largely restricted to sicker patients. In a post hoc analysis of
the Beta Blocker Heart Attack Trial (BHAT), patients who
had experienced either electrical or mechanical complications,
or both, with their MI had large reductions in mortality
during the 25-month follow-up period, whereas 55% of pa-
tients without these complications had only a small reduction
in mortality (adjusted hazard ratio, 0.96).11
In a meta-analysis reported by 1 of us, 60 randomized trials
of b-blockers with 102,003 patients who had experienced MI
were included.10 Trials were categorized into the reperfusion
era (deﬁned as > 50% of patients undergoing coronary
reperfusion or receiving aspirin and a statin drug) or pre-
reperfusion era trials. In trials of acute MI, a signiﬁcant
interaction (P ¼ 0.02) was noted such that b-blockers reduced
mortality in the pre-reperfusion era (incident rate ratio [IRR]
0.86; 95% conﬁdence interval [CI], 0.79-0.94) but not in the
reperfusion era (IRR, 0.98; 95% CI, 0.92-1.05), as illustrated
in Figure 1.
In the pre-reperfusion era, b-blockers reduced cardiovas-
cular mortality (IRR, 0.87; 95% CI, 0.78-0.98), MI (IRR,
0.78; 95% CI, 0.62-0.97), and angina (IRR, 0.88; 95% CI,
0.82-0.95), with no difference for other outcomes. In the
reperfusion era, b-blockers also reduced MI (IRR, 0.72; 95%
CI, 0.62-0.83) and angina (IRR, 0.80; 95% CI, 0.65-0.98)
but at the expense of an increase in heart failure (IRR, 1.10;
95% CI, 1.05-1.16), cardiogenic shock (IRR, 1.29; 95% CI,
1.18-1.41), and drug discontinuation (IRR, 1.64; 95% CI,
1.55-1.73), with no beneﬁt for other outcomes. Beneﬁts for
recurrent MI and angina in the reperfusion era appeared to be
limited to the ﬁrst 30 days.
One explanation for the failure of b-blockers to reduce
mortality in the reperfusion era is that the substrate has
changeddmost patients with MI no longer are left with an
occluded artery and a large infarcted area that facilitates
electrical and mechanical complications. Mortality after MI in
the era before reperfusion was driven mainly by sudden car-
diac death, a complication that b-blockers prevents. With
sudden cardiac death being less of a problem, b-blockers are
less of a solution.
Another possibility is that b-blockers provide no added
reduction in mortality in addition to other guideline-
mandated treatmentsdspeciﬁcally, aspirin and other anti-
platelet therapy, ACE inhibitors, and statin drugs. In the First
International Study of Infarct Survival trial (ISIS-1), only 5%
of patients received an antiplatelet agent at discharge, and no
one was treated with reperfusion, yet atenolol signiﬁcantly
reduced vascular death when compared with controls.12
Conversely, in the Clopidogrel and Metoprolol inMyocardial Infarction Trial (COMMIT), all patients received
aspirin, 50% received DAPT, two-thirds got an ACE inhib-
itor, and 54% received ﬁbrinolytic agents.13 Metoprolol was
not superior to placebo for both of the coprimary end points:
30-day mortality and 30-day death/MI or cardiac arrest,
despite almost 3 times the sample size and greater statistical
power than ISIS-1.Adverse Metabolic Effects of b-Blockers
b-Blockers increase the incidence of new-onset diabetes
(NOD) to a greater degree than statins do.14 In a meta-
analysis of 12 studies involving 94,492 patients, b-blocker
use was associated with a 22% increase in NOD (relative risk,
1.22; 95% CI, 1.12-1.33) compared with nondiuretic anti-
hypertensive agents.15 The risk of NOD increased exponen-
tially with duration of treatment. This is different from the
pattern with thiazide diuretics, in which NOD occurs mainly
in the ﬁrst year, or with statin drugs, in which the increased
risk of NOD appears to be constant over time.14
b-Blockers increase the risk of NOD both by inhibiting
insulin secretion and by inducing insulin resistance.14 The risk
of NOD with b-blockers is mitigated by the concomitant use
of an ACE inhibitor. In patients with established diabetes,
older b-blockers worsen glucose control, but newer b1-
selective blockers appear to have little or no effect, at least in
short-term studies.14
In the pre-reperfusion era, when recurrent events after MI
could be attributed to large myocardial scars, continued
smoking, and untreated cholesterol levels, the long-term
metabolic consequences of b-blockers were less worrisome.
Also, fewer patients survived long-term. Contemporary pa-
tients who have experienced MI are more likely to have pre-
diabetes and obesity and are less likely to smoke and have
untreated lipid levels. Under these conditions, and with
improved long-term survival, the metabolic consequences of
b-blockers are more troublesome.When Should We Prescribe b-Blockers After MI?
Many patients with MI today still resemble patients with
MI from the pre-reperfusion era, with an occluded culprit
coronary artery and large infarct zone. They should be treated
with a b-blocker with the expectation that they will beneﬁt
similarly to patients who have experienced MI in the older
b-blocker post-MI trials. Patients with heart failure experience
fewer hospitalizations and better survival with a b-blocker.
These agents also still have a role, although diminished, in the
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condition after MI.
Most MIs now occur in low- and middle-income coun-
tries, where the incidence is rising.16 Patients in these coun-
tries are less likely to receive timely reperfusion therapy
compared with patients in high-income countries and are
more likely to leave the hospital with the substrate in which
b-blockers are helpful. This segment of the worldwide MI
population is likely to grow as unchecked risk factors prolif-
erate in low- and middle-income countries.
With these important exceptions, the evidence does not
appear to support the use of b-blockers in modern patients
who have experienced MIdthose who have had their culprit
artery stented and have only minor residual myocardial
damage. DAPT, ACE inhibitors, and statin drugs are indi-
cated, based on the results of clinical trials that enrolled pa-
tients such as these. Consideration could be given to offering a
b-blocker for 1 month to reduce repeated infarction and
angina, but the trade-off would be a slightly increased risk of
heart failure.Guidelines
Guidelines recommend that b-blockers be given routinely
to patients after MI,7,8,17 and health care organizations have
adopted b-blocker use at discharge after an MI as a quality
indicator.10 As guidelines have proliferated and expanded,
attempts have been made to make them entirely evidence-
based, with well-conducted clinical trials being the best
form of evidence.18 Do guideline committees have the scope
to conclude that perhaps as a disease has evolved, the relevant
clinical trials may not be relevant any more, at least for most
patients?
Some of “these truths that we hold to be self-evident” may
no longer be true at all. The evidence has shifted. The
cardiologist who considers ignoring a guideline might take
solace from other words from Thomas Jefferson:I hold it, that a little rebellion, now and then, is a good thing, and as
necessary in the political world as storms in the physical.
dThomas JeffersonDisclosures
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